Vaginal estrogen for genitourinary syndrome of menopause

Obstetrics and Gynecology

Volumn 124, Issue 6, 2014, Pages 1147-1156

  Rahn, David D ^a   Carberry, Cassandra ^b   Sanses, Tatiana V ^b   Mamik, Mamta M ^b   Ward, Renée M ^b   Meriwether, Kate V ^b   Olivera, Cedric K ^b   Abed, Husam ^b   Balk, Ethan M ^b   Murphy, Miles ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; UNCLASSIFIED DRUG; VAGINAL ESTROGEN;

CONFERENCE PAPER; DYSPAREUNIA; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE GENITAL PRURITUS; HUMAN; MENOPAUSE; OVERACTIVE BLADDER; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STRESS INCONTINENCE; SYSTEMATIC REVIEW; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL SYSTEM; VAGINA ATROPHY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; ATROPHIC VAGINITIS; COMPLICATION; INTRAVAGINAL DRUG ADMINISTRATION; UROLOGIC DISEASES;

ADMINISTRATION, INTRAVAGINAL; ATROPHIC VAGINITIS; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; UROLOGIC DISEASES;

EID: 84916880393     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000526     Document Type: Conference Paper

References (66)

1. Portman DJ, Gass ML. Vulvovaginal atrophy terminology consensus conference panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause 2014; 21:1063-8.
2. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: women's health initiative. Maturitas 2004;49:292-303.
3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-42.
4. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790-9.
5. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013;20:888-902.
6. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:202-16.
7. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in postmenopausal women. The Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No.: CD001405. DOI: 10.1002/14651858.CD001405.pub3.
8. Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and metaanalysis of randomized controlled trials. J Urol 2013;190: 1981-9.
9. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause 2013;20: 1043-8.
10. Shulman LP, Portman DJ, Lee WC, Balu S, Joshi AV, Cobden D, et al. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice. J Womens Health (Larchmt) 2008;17:569-78.
11. Institute of Medicine. Finding what works in health care: standards for systematic reviews. Washington, DC: The National Academies Press; 2011.
12. Wallace BC, Trikalinos TA, Lau J, Brodley C, Schmid CH. Semi-automated screening of biomedical citations for systematic reviews. BMC Bioinformatics 2010;11:55.
13. Rahn DD, Mamik MM, Sanses TV, Matteson KA, Aschkenazi SO, Washington BB, et al. Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol 2011;118:1111-25.
14. Sung VW, Rogers RG, Schaffer JI, Balk EM, Uhlig K, Lau J, et al. Graft use in transvaginal pelvic organ prolapse repair: a systematic review. Obstet Gynecol 2008;112:1131-42.
15. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions- Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol 2010;63: 513-23.
16. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches. The GRADE Working Group. BMC Health Serv Res 2004;4:38.
17. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.
18. Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-27.
19. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130-9.
20. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women - a double-blind placebo-controlled study. J Obstet Gynaecol 2001;21:383-5.
21. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebocontrolled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:171-6.
22. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004; 11:49-56.
23. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 1992;44:137-44.
24. Foidart JM, Vervliet J, Buytaert P. Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 1991;13:99-107.
25. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twiceweekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009;16:735-41.
26. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012;71:360-8.
27. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993;329:753-6.
28. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-lowdose estradiol vaginal tablet. Obstet Gynecol 2008;112: 1053-60.
29. Simuní V, Banoví I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003;82:187-97.
30. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999;180:1072-9.
31. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-8.
32. Bachmann G, Notelovitz M, Nachtigall L, Birgerson L. A comparative study of a low-dose estradiol vaginal ring and conjugated estrogen cream for postmenopausal urogenital atrophy. Prim Care Update 1997;4:109-15.
33. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22(suppl):S43-7.
34. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73-80.
35. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. Arch Gynecol Obstet 2012;285:397-403.
36. Chompootaweep S, Nunthapisud P, Trivijitsilp P, Sentrakul P, Dusitsin N. The use of two estrogen preparations (a combined contraceptive pill versus conjugated estrogen cream) intravaginally to treat urogenital symptoms in postmenopausal Thai women: a comparative study. Clin Pharmacol Ther 1998;64:204-10.
37. Dickerson J, Bressler R, Christian CD, Hermann HW. Efficacy of estradiol vaginal cream in postmenopausal women. Clin Pharmacol Ther 1979;26:502-7.
38. Dugal R, Hesla K, Sørdal T, Aase KH, Lilleeidet O, Wickstrøm E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-7.
39. Henriksson L, Stjernquist M, Boquist L, Alander U, Selinus I. A comparativemulticenter study of the effects of continuous low-dose estradiol released from a new vaginal ring versus estriol vaginal pessaries in postmenopausal women with symptoms and signs of urogenital atrophy. Am J Obstet Gynecol 1994;171:624-32.
40. Kicovic PM, Cortes-Prieto J, Milojeví S, Haspels AA, Aljinovic A. The treatment of postmenopausal vaginal atrophy with Ovestin vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas 1980;2:275-82.
41. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000;107:1029-34.
42. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gyneacol Res 2001;27:255-60.
43. Mattsson LA, Cullberg G. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand 1983;62:397-401.
44. Mattsson LA, Cullberg G, Eriksson O, Knutsson F. Vaginal administration of low-dose oestradiol - effects on the endometrium and vaginal cytology. Maturitas 1989;11:217-22.
45. Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14:23-31.
46. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-61.
47. Trevoux R, van der Velden WH, Popovic D. Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduccion 1982;6:101-6.
48. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92.
49. Antoniou G, Kalogirou D, Karakitsos P, Antoniou D, Kalogirou O, Giannikos L. Transdermal estrogen with a levonorgestrel- releasing intrauterine device for climacteric complaints versus estradiol-releasing vaginal ring with a vaginal progesterone suppository: clinical and endometrial responses. Maturitas 1997;26:103-11.
50. Botsis D, Kassanos D, Kalogirou D, Antoniou G, Vitoratos N, Karakitsos P. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison.Maturitas 1997;26:57-62.
51. Gupta P, Ozel B, Stanczyk FZ, Felix JC, Mishell DR Jr. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Menopause 2008;15:94-7.
52. Holmgren PA, Lindskog M, von Schoultz B. Vaginal rings for continuous low-dose release of oestradiol in the treatment of urogenital atrophy. Maturitas 1989;11:55-63.
53. Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006;85: 155-60.
54. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-43.
55. Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 2010;26: 404-12.
56. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet 2011; 283:539-43.
57. Nachtigall LE. Comparative study: replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-80.
58. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr, et al. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-52.
59. Kessel B, Nachtigall L, Plouffe L, Siddhanti S, Rosen A, Parsons A. Effect of raloxifene on sexual function in postmenopausal women. Climacteric 2003;6:248-56.
60. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7: 1284-90.
61. Pinkerton JV, Shifren JL, La Valleur J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:45-52.
62. Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003;36:1362-8.
63. Lee YK, Chung HH, Kim JW, Park NH, Song YS, Kang SB. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011;117:922-7.
64. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-7.
65. Committee on Practice Bulletins-Gynecology. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:666-82.
66. Nelson RE, Grebe SK, DJ OK, Singh RJ. Liquid chromatographytandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 2004;50: 373-84.